TRT and Cholesterol: Why HDL Drops and When It Matters

The Short Answer

What Testosterone Does to Your Lipid Panel

A frequently cited summary is a 2001 meta-analysis of 19 studies of testosterone injections in hypogonadal men, published in the American Journal of Medicine. On average, total cholesterol fell 14 mg/dL, LDL fell 5 mg/dL and HDL fell 4 mg/dL. The authors called the HDL change small and dosage-dependent, and said its overall effect on cardiovascular risk was unknown. The studies were published between 1987 and 1999, so they reflect older products and protocols.

A 2005 meta-analysis of 29 trials in middle-aged and older men (average age about 64) found a similar pattern: total cholesterol dropped, LDL didn't change, and a significant HDL drop showed up only in studies where men started with higher testosterone levels.

Label language is mixed. The Kyzatrex label (an oral capsule) says patients in its clinical trials saw reductions in total cholesterol, LDL, HDL and triglycerides. The Jatenzo label, another oral product, lists "high-density lipoprotein decreased" as an adverse reaction in 3.0% of patients. The Depo-Testosterone label (injectable testosterone cypionate) says only that serum cholesterol may increase during androgen therapy, so labels do not agree on total cholesterol.

So most of the panel moves slightly down. HDL is the number that moves the "wrong" way, which is why it gets the attention.

What May Drive the HDL Drop

Two possible mechanisms show up in human studies. First, testosterone can raise the activity of hepatic lipase, a liver enzyme, and HDL fell alongside it. In a 2003 study in older, obese men with normal testosterone, a supraphysiologic dose of 600 mg a week for three weeks pushed hepatic lipase activity more than 60% above baseline, and HDL, HDL2 and HDL3 all declined. That dose is far above replacement, so the size of this effect at typical TRT doses is less certain.

Second, estradiol, which your body makes from testosterone, appears to help hold HDL up. In a 1994 study in healthy young men, researchers replaced testosterone and blocked its conversion to estradiol with an aromatase inhibitor (testolactone). HDL fell, especially the HDL2 fraction, while men given testosterone without the inhibitor had no statistically significant HDL drop. The authors concluded that normal estradiol levels help maintain HDL.

That second finding matters on TRT. Based on that study, aggressively suppressing estradiol with an aromatase inhibitor could add to an HDL drop. It's one more reason to be cautious about routine AI use; see the case for restraint with aromatase inhibitors.

Dose and Route: Where the HDL Effect Gets Bigger

The clearest pattern is dose. In a 2001 dose-response trial, 61 young men had their own testosterone suppressed and received 25, 50, 125, 300 or 600 mg of testosterone enanthate weekly for 20 weeks. Average trough levels ranged from 253 to 2,370 ng/dL across the groups, and HDL changes were negatively correlated with dose: more testosterone, lower HDL.

In a separate study of 200 mg of testosterone enanthate a week in men who started with normal testosterone, HDL fell 15–20%. The drop held through 12 months of treatment and reversed within one month of stopping.

Route is less clear. We couldn't find a large head-to-head trial comparing injections, gels and oral capsules on HDL. What the evidence does show: the injection meta-analysis found a small, dose-dependent drop, and the labels for the oral testosterone undecanoate capsules report HDL reductions (more on those products in our oral TRT guide).

The practical lever is dose and the blood level it produces. The Endocrine Society suggests aiming for the mid-normal range, and the AUA describes that middle range as roughly 450–600 ng/dL for most labs. If your levels run well above that, your HDL is one of several reasons to revisit the dose.

Does Lower HDL Mean More Heart Attacks? What TRAVERSE Showed

Outcome data beat lab markers, and TRAVERSE is the largest outcome trial we have. Per the summary in FDA-approved testosterone gel labeling, it enrolled about 5,200 hypogonadal men aged 45 to 80 with heart disease or multiple risk factors. Major adverse cardiovascular events, a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke, occurred in 7.0% on testosterone gel and 7.3% on placebo (hazard ratio 0.96; 95% CI 0.78–1.17), meeting the trial's non-inferiority goal. Mean treatment lasted about 22 months, with 33 months of follow-up.

TRAVERSE wasn't all clean. The same labeling reports more nonfatal arrhythmias needing intervention (5.2% vs 3.3%), atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and pulmonary embolism (0.9% vs 0.5%) on testosterone. In February 2025 the FDA removed cardiovascular-outcomes language from the boxed warning on testosterone products and added a warning about blood pressure increases.

Imaging studies are mixed. In the Testosterone Trials, 138 older men with coronary CT scans saw noncalcified plaque volume rise more on testosterone than on placebo, according to the investigators' Endocrine Reviews summary. But in the three-year TEAAM trial of 308 men aged 60 and older, testosterone gel made no significant difference in carotid wall thickening or coronary calcium progression. The trial enrolled men with low or low-normal testosterone and was built to measure artery changes, not heart attacks or strokes.

HDL itself may also be a weaker signal than people assume. A Mendelian randomization study in The Lancet found that a gene variant raising HDL wasn't associated with lower heart attack risk, while a genetic score for LDL did track with risk. That doesn't prove a testosterone-driven HDL drop is harmless, but it does mean HDL alone is a poor guide. For the full trial story, see TRAVERSE explained.

Which Lipid Labs to Track on TRT

The Testim label now says to monitor the lipid profile periodically, particularly after starting testosterone and after dose increases. Here's a practical set to discuss with your prescriber.

Guideline details come from the American College of Cardiology's summary of the 2026 guideline. Our posts on blood pressure monitoring and the 14-marker blood panel cover the rest of the workup.

Don't assume your TRT clinic checks lipids. Some clinic intake panels focus on hormones and blood counts; TRT Nation's required markers, for example, are total testosterone, CBC, CMP, sensitive estradiol and, for men over 40, PSA, with no lipid panel listed. If yours doesn't include one, ask your primary care doctor, or add it to your own draw if you bring outside labs.

If Your HDL Drops: What to Discuss With Your Prescriber

• Look at your testosterone level. Because HDL falls more at higher doses, a level above mid-normal is the first thing to check. Make sure the draw timing makes sense for your schedule; see trough draw timing.
• Look at estradiol and any aromatase inhibitor. Blocking estradiol production lowered HDL in the 1994 study. If you're on an AI, ask whether you still need it.
• Weigh the whole panel. The 2026 ACC/AHA guideline frames its treatment goals around LDL and non-HDL cholesterol: LDL below 100 mg/dL for borderline or intermediate 10-year risk, and LDL below 70 plus non-HDL below 100 for high risk (10% or more on the PREVENT calculator).
• Coordinate with your other medications. The Kyzatrex and Jatenzo labels say lipid changes may require adjusting lipid-lowering drugs or stopping testosterone. Don't change either on your own.
• Remember it's reversible. In the 200 mg-a-week study, HDL recovered within a month of stopping. That doesn't show how much a smaller dose would help, but because HDL falls as dose rises, a dose review is a reasonable first topic to raise with your prescriber.

The Bottom Line

A small HDL drop is a common, dose-related effect of testosterone, and TRAVERSE didn't find a higher rate of heart attacks, strokes or cardiovascular deaths combined in men using testosterone gel. That's reassuring, but it isn't a reason to skip lipid monitoring. The other TRAVERSE signals, such as atrial fibrillation and clots, deserve as much attention as your cholesterol numbers.

Next steps: get a baseline lipid panel, recheck after starting and after any dose increase, measure Lp(a) once, and keep testosterone in the mid-normal range. If HDL falls, look at dose and estradiol before anything else. For the broader heart-risk picture, read what comes after TRAVERSE.